The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2

被引:10
|
作者
Jamous, Yahya F. [1 ]
Alhomoud, Dalal A. [1 ]
机构
[1] King Abdulaziz City Sci & Technol, Natl Ctr Vaccine & Bioproc, Riyadh, Saudi Arabia
关键词
safety; efficacy; vaccines; mrna; sars-cov-2; COVID-19; VACCINE; HYPERSENSITIVITY; OUTCOMES; SEX;
D O I
10.7759/cureus.45602
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and PfizerBioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2
    Huang, Hai
    Zhang, Caili
    Yang, Shuping
    Xiao, Wen
    Zheng, Qian
    Song, Xiangrong
    JOURNAL OF CONTROLLED RELEASE, 2021, 335 : 449 - 456
  • [42] Comparison of DNA vaccines with AS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2
    Neeli, Praveen
    Chai, Dafei
    Wang, Xu
    Sobhani, Navid
    Udeani, George
    Li, Yong
    ISCIENCE, 2023, 26 (07)
  • [43] Diagnosis of Acute Myocarditis Following mRNA Vaccines against SARS-CoV-2: A Methodological Review
    Zuin, Marco
    Zimelli, Emma
    Dalla Valle, Chiara
    Cavedon, Stefano
    Rigatelli, Gianluca
    Bilato, Claudio
    VIRUSES-BASEL, 2023, 15 (04):
  • [44] DELAYED SKIN REACTIONS AFTER THE SECOND DOSE OF MRNA VACCINES AGAINST SARS-COV-2
    Martins-Filho, Paulo Ricardo
    Tenorio, Martha Debora Lira
    EXCLI JOURNAL, 2022, 21 : 1015 - 1018
  • [45] SARS-CoV-2 Vaccines
    Creech, C. Buddy
    Walker, Shannon C.
    Samuels, Robert J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (13): : 1318 - 1320
  • [46] SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
    Singh, Desh Deepak
    Parveen, Amna
    Yadav, Dharmendra Kumar
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [47] Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines
    Belizario, J. E.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2021, 54 (05)
  • [48] Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over
    Alicandro, Gianfranco
    Dacco, Valeria
    Cariani, Lisa
    Contarini, Martina
    Morlacchi, Letizia Corinna
    Rosazza, Chiara
    Sciarrabba, Calogero Sathya
    Ferraro, Federica
    Lanfranchi, Chiara
    Orena, Beatrice Silvia
    Gramegna, Andrea
    Blasi, Francesco
    Colombo, Carla
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (03) : E173 - E175
  • [49] Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
    Chao, Chiao-Hsuan
    Cheng, Dayna
    Huang, Sheng-Wen
    Chuang, Yung-Chun
    Yeh, Trai-Ming
    Wang, Jen-Ren
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [50] Response to "Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis"
    Deng, Jiawen
    Heybati, Kiyan
    Zhou, Fangwen
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (12) : 6477 - 6478